The FDA recently approved two new treatments for an ancient scourge, sickle-cell anemia. Vertex Pharmaceuticals’ Casgevy and Bluebird Bio’s Lyfgenia are not prescription drugs, but processes that genetically modify a patient’s own cells before they are then returned to the patient.
The treatments could be groundbreaking, but with them come multiple questions.
Charles Horton is an anesthesiologist who loves both the art and the science of medicine.
